These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 10071302)

  • 21. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
    de Bono JS; Tolcher AW; Rowinsky EK
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):79-92. PubMed ID: 14613029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibiting Ras signaling in the therapy of breast cancer.
    Li T; Sparano JA
    Clin Breast Cancer; 2003 Feb; 3(6):405-16; discussion 417-20. PubMed ID: 12636885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of the immune response and tumor growth by activated Ras.
    Weijzen S; Velders MP; Kast WM
    Leukemia; 1999 Apr; 13(4):502-13. PubMed ID: 10214854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An overview of farnesyltransferase inhibitors and their role in lung cancer therapy.
    Adjei AA
    Lung Cancer; 2003 Aug; 41 Suppl 1():S55-62. PubMed ID: 12867063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
    Karp JE; Lancet JE
    Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition.
    Dorrell C; Takenaka K; Minden MD; Hawley RG; Dick JE
    Mol Cell Biol; 2004 Aug; 24(16):6993-7002. PubMed ID: 15282300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anti tumor activity of farnesyl transferase inhibitor].
    Yoshimatsu K; Nagasu T
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy.
    Sebti SM; Hamilton AD
    Pharmacol Ther; 1997; 74(1):103-14. PubMed ID: 9336018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
    Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
    Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
    Lebowitz PF; Prendergast GC
    Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blocked pathways: FTIs shut down oncogene signals.
    Sebti SM
    Oncologist; 2003; 8 Suppl 3():30-8. PubMed ID: 14671226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ras processing as a therapeutic target in hematologic malignancies.
    Le DT; Shannon KM
    Curr Opin Hematol; 2002 Jul; 9(4):308-15. PubMed ID: 12042705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
    Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
    J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Farnesyltransferase inhibitors: targeting the molecular basis of cancer.
    Oliff A
    Biochim Biophys Acta; 1999 May; 1423(3):C19-30. PubMed ID: 10382537
    [No Abstract]   [Full Text] [Related]  

  • 35. [Farnesyl transferase inhibitors--a novel agent for breast cancer].
    Zhang M; Jiang D
    Ai Zheng; 2006 Apr; 25(4):516-20. PubMed ID: 16613692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
    Mangues R; Corral T; Kohl NE; Symmans WF; Lu S; Malumbres M; Gibbs JB; Oliff A; Pellicer A
    Cancer Res; 1998 Mar; 58(6):1253-9. PubMed ID: 9515813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Farnesyl transferase inhibitors: one target may be found in another].
    Mazières J; Pradines A; Favre G
    Med Sci (Paris); 2003 Feb; 19(2):211-6. PubMed ID: 12836615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
    Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
    Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ras inhibitors and radiation therapy.
    Jones HA; Hahn SM; Bernhard E; McKenna WG
    Semin Radiat Oncol; 2001 Oct; 11(4):328-37. PubMed ID: 11677657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS.
    Beaupre DM; Talpaz M; Marini FC; Cristiano RJ; Roth JA; Estrov Z; Albitar M; Freedman MH; Kurzrock R
    Cancer Res; 1999 Jun; 59(12):2971-80. PubMed ID: 10383163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.